Dr. Rachel Wen-Juei Jeng is a Professor at Chang Gung University and an attending hepatologist at Chang Gung Memorial Hospital (CGMH), Linkou, Taiwan. She has also served as a physician-scientist and Deputy Director of the Clinical Trial Center at CGMH since 2019.

Dr. Jeng received her MD from National Yang-Ming University in 2005 and her PhD from the same institution in 2022. She completed her clinical training in internal medicine and gastroenterology at CGMH.

Her research focuses on chronic hepatitis B (HBV), encompassing the natural history of HBV infection, antiviral treatment strategies, finite nucleos(t)ide analogue therapy, and emerging therapies aimed at achieving functional cure. She has published extensively on the clinical outcomes of antiviral treatment withdrawal, predictors of virological relapse and HBsAg loss, and strategies for optimizing patient selection and post-treatment monitoring. She is also actively involved in clinical trials and translational research evaluating novel HBV therapeutics.

Dr. Jeng has served as an Associate Editor of the Journal of Hepatology since October 2024 and is a member of the Editorial Board of Hepatology Communications. She currently serves as Deputy Secretary-General of the Taiwan Association for the Study of the Liver (TASL) and is a Fellow of the American Association for the Study of Liver Diseases (FAASLD). She is also an active member of the European Association for the Study of the Liver (EASL).